Participants will receive an intravenous infusion of aducanumab at 10 mg/kg monthly for 2 years, and eligible participants will continue to receive the infusion for another 52 weeks during the long-term extended treatment period. The primary outcomes are safety and tolerability, and the efficacy ...
ultimately led to the formation of the “Expert Consensus on the Rational Clinical Use of Nationally Monitored Drugs Beyond Their Approved Indications.”ResultsA survey questionnaire was conducted among 60 experts through an online survey,and a consensus on off-label use items was reached using the ...
However, sometimes the diagnosis is difficult to establish, as some patients are asymptomatic [10], or they may present signs and symptoms characteristic of other common pathologies, or they may be masked by prior self-administration of analgesics, anti-inflammatory drugs or even antibiotics. For ...
“health technology” is defined as any intervention used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, including drugs, devices, procedures, settings of care, and screening (15). Clinical trials units are also eligible to apply for NIHR Clinical ...
29 clinical experts are (previously) served as the chairman and deputy chairman of the provincial medical society/Associations and above, 52% of them enjoy long-term (≥1 years) experience of overseas practice, research and further training, 92% of the doctors was introduced from outside Shenzhe...
PARP inhibitors combined with other drugs will hopefully overcome their limitations and improve their therapeutic efficacy. In addition to the drugs mentioned above, there are other promising combination treatments for PARP inhibitors. At present, most of the clinical trials on the combination of PARP ...
Pragmatic clinical trials “inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice.”
1,083 participants into groups receiving placebo or 50 or 100 mg of simufilam (1:1:1) for 76 weeks. The primary outcome measures are similar to those of the RETHINK-ALZ trial. A phase 3 trial of simufilam (NCT05575076) was started in November 2022 to assess the long-term safety ...
eFigure.Analysis Flow Charts From Search Term Inputs to Development Research Funding Data eTable 1.Drug and Biological Target Search Terms Used in PMID Extraction eTable 2.Estimated Sensitivity and Specificity of Discovered Developmental and Clinical PMIDs ...
Long-term controlled delivery of therapeutic agents via an implantable osmotically driven system: the DUROS implant. Drugs Pharm. Sci. 126, 657–670 (2003). CAS Google Scholar Wykoff, C. C., Hariprasad, S. M. & Zhou, B. Innovation in neovascular age-related macular degeneration: ...